advanceCor Revenue

About advanceCor

Personalised therapies for the heart and vasculature Innovative, independent, close to the patient. We are a biotech company that independently develops innovative drugs and diagnostics for personalised treatment of cardiovascular diseases. We have a unique product pipeline that we are consistently moving into clinical trials. Our lead compound has been successfully tested in two Phase II studies. We work closely together with excellent academic and clinical teams in basic and clinical research. We use state-of-the-art analytical methods, and we develop our products according to the highest quality standards (GLP, GMP and GCP). Revacept is a therapeutic agent for the prevention and treatment of acute arterial thrombosis, which can lead to heart attack, acute limb ischemia and stroke. A Phase II clinical trial in 160 patients with stroke or transient ischaemic attack (TIA) has been completed. It showed beneficial effects in patients treated with 120 milligrams (mg) of Revacept. Another Phase II clinical trial investigated Revacept in 332 patients with stable coronary artery disease (ISAR-PLASTER) has been completed. This study conducted by the German Centre for Cardiovascular Research (DZHK) confirmed the very good tolerability of Revacept. Overall, Revacept did not lead to increased bleeding despite of its additional platelet aggregation inhibition on top of conventional standard therapy. It decreased ischemic strokes in NMR and improved the net clinical benefit of MACE and bleeding. Recently, the FDA has approved the preclinical and clinical development and the further phase 3 protocol until market approval. Antibody therapeutic In collaboration with Morphosys an anti-GPVI Fab antibody has been discovered. The candidate is currently in preclinical evaluation for the treatment of acute coronary syndrome and stroke. Imprint: https://www.advancecor.de/imprint/ privacy policy: https://www.advancecor.de/privacy-policy/

View contact profiles from advanceCor